Back to search results

Understanding and Preventing Gastric Cancer

This observational study aims to create a registry of people with conditions that can lead to stomach cancer (gastric atrophy, intestinal metaplasia, and dysplasia). Researchers will also include healthy individuals and those with stomach cancer for comparison. The study involves completing a questionnaire about your health, environment, lifestyle, and diet. The main goal is to build this registry over a period of up to 10 years to better understand and prevent gastric cancer. You may be eligible if you are 18 or older, can read English or Spanish, and have a diagnosis of gastric atrophy, intestinal metaplasia, or dysplasia.

Study design
This is an observational study that plans to enroll 3200 participants. It is not testing a new treatment but rather collecting health information.
What's involved
You would complete a questionnaire about your clinical history, environment, lifestyle, and diet.
Compensation
Not stated in the trial record.
Follow-up
The study aims to create a participant registry over a period of up to 10 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06370143

A Study Collecting Health Information to Understand and Prevent Gastric Cancer

Recruiting
Not specifiedAges 18+Observational
Memorial Sloan Kettering Cancer Center
~3,200 participants
Updated 2026-01-30 on ClinicalTrials.gov
What's tested:Questionnaire

At a glance

Recruiting sites
7 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Creation of participant registry
Measured over Up to 10 years

Conditions

Gastric Atrophy
Gastric Intestinal Metaplasia
Dysplasia
Gastric Adenocarcinoma
Gastric Cancer

Explore related trials

Chronic Atrophic GastritisDysplasiaGastric CarcinomaIntestinal Metaplasia of Gastric Mucosa

Where it's being run

7 sites across 2 states
New York4
New Jersey3

Study leadership

  • Monika Laszkowska, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Monika Laszkowska, MD
[email protected]
212-639-6857
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years old
Able to read and understand English and Spanish
Meet criteria for one of three potentially eligible study populations:
Individuals with gastric atrophy, gastric intestinal metaplasia, or dysplasia: Had a previous diagnosis of or have been diagnosed by the investigation team with gastric atrophy, gastric intestinal metaplasia, or dysplasia of the gastric mucosa on pathology review from an endoscopic biopsy. Individuals who have a prior history of early gastric cancer may be included, if they were treated endoscopically and have no evidence of disease. Individuals who have a prior history of a cancer other than upper gastrointestinal cancer may also be included, if they have no evidence of disease for at least 1 year prior to study enrollment and are not undergoing active treatment for any malignancy at any time throughout the study period
Healthy controls (average risk): Individuals with no history of cancer or gastric precursor lesions undergoing a clinically indicated endoscopy at MSK for workup or dyspepsia or reflux
Gastric cancer cases: Individuals with a known diagnosis of early gastric adenocarcinoma undergoing surgical resection at MSK

Exclusion

Age \< 18 years old
Women who are pregnant (may be enrolled after delivery)
Individuals with a prior history of upper gastrointestinal surgery or a prior cancer who are undergoing active treatment for malignancy or have been diagnosed within 1 year prior to the study enrollment or with pancreatic cancer. (This does not include incidentally diagnosed primary gastric adenocarcinoma identified during study follow up. Individuals diagnosed with gastric carcinoid limited to the stomach will also be included, given their ongoing parallel risk for gastric adenocarcinoma.)
Have severe comorbidities with expected survival time \<2 years or which would prevent them from undergoing routine elective EGD (at the discretion of the patient's provider and the study team)
Individuals having Hereditary Diffuse Gastric Cancer Syndrome, mutations including CDH1 and CTNNA1, or more than one genetic mutation
Exclude high risk esophageal and duodenal lesions including:
Duodenal Adenoma
Dysplasia or cancer at the esophagus or gastroesophageal junction
Patients with an increased risk for biopsies during EGD, such as those with clotting disorders.

What this trial measures

  • Creation of participant registryUp to 10 years

    The primary objective of this study is to create a registry of individuals with precursor lesions for gastric cancer, including gastric atrophy, intestinal metaplasia, and dysplasia. Normal controls and individuals with gastric cancer for comparison of baseline characteristics will also be enrolled.